Flordis launches Ellura
February 25, 2014
Flordis Natural Medicines has
enlisted strong support for the
launch of its new Ellura cranberry-based
supplement, in the form of
Dr Amy Howell, Associate Research
Scientist at Rutgers University in
the USA, who visited Australia last
week highlighting clinical evidence
for the product and its action to
promote urinary tract health.
Howell, who’s pictured above
centre with Nick Burgess and Liisa
Lewis from Flordis, has led studies
which have shown that Ellura has
a dose-dependent and fast acting
effect, significantly increasing
bacterial anti-adhesion activity
in urine samples collected from
subjects who took Ellura versus a
placebo in a randomised double-blind
clinical trial.
Ellura is a unique extract from
American cranberries (vaccinium
macrocarpon) which has been
standardised so that each capsule
provides the recommended dose of
36mg of proanthocyanidins (PACs)
- equivalent to the juice of 70g of
fresh cranberry fruit.
“Cranberries play an important
role in preventing antibiotic
resistant bacteria from colonising
the urinary tract, and therefore...
may help to reduce the frequency
of recurrent cystitis,” Howell said.
She said the efficacy of the
specific 36mg dosage had been
evaluated in several trials and is
“important in distinguishing Ellura
from other cranberry formulations”.
Ellura is now available in
community pharmacies and select
health food stores nationally.
The above article was sent to subscribers in Pharmacy Daily's issue from 25 Feb 14To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Feb 14
